

PSORIASIS

## SWITCH BETWEEN INTERLEUKIN-17A ANTAGONISTS FOR PSORIASIS: A FRENCH MULTICENTRIC RETROSPECTIVE EXPERIENCE

*Ac Fougereuse<sup>(1)</sup> - C Boulard<sup>(2)</sup> - E Begon<sup>(3)</sup> - F Maccari<sup>(4)</sup> - L Mery<sup>(5)</sup> - H Barthelemy<sup>(6)</sup> -  
Ac Cottencin<sup>(7)</sup> - Jb Monfort<sup>(8)</sup> - N Sultan<sup>(9)</sup> - D Lons Danic<sup>(10)</sup> - J Parier<sup>(11)</sup> - C  
Jacobzone<sup>(12)</sup> - C Girard<sup>(13)</sup> - Z Reguiat<sup>(14)</sup> - E Mahe<sup>(15)</sup> - Gem Resopso<sup>(16)</sup>*

*Hia Begin, Dermatology, Saint Mandé, France<sup>(1)</sup> - Ch Havre, Dermatology, Le Havre,  
France<sup>(2)</sup> - Ch Pontoise, Dermatology, Pontoise, France<sup>(3)</sup> - Hia Begin, Dermatology, Saint  
Mandé, France<sup>(4)</sup> - Ch Mantes La Jolie, Dermatology, Mantes La Jolie, France<sup>(5)</sup> - Ch  
Auxerre, Dermatology, Auxerre, France<sup>(6)</sup> - Chu Lille, Dermatology, Lille, France<sup>(7)</sup> - Chu  
Tenon, Dermatology, Paris, France<sup>(8)</sup> - Ch Saint Paul, Dermatology, Saint Paul, France<sup>(9)</sup> -  
Hopital Saint Joseph, Dermatology, Paris, France<sup>(10)</sup> - Private Practice, Dermatology, La  
Varenne Saint Hilaire, France<sup>(11)</sup> - Ch Lorient, Dermatology, Lorient, France<sup>(12)</sup> - Chu  
Montpellier, Dermatology, Montpellier, France<sup>(13)</sup> - Clinique Courlancy, Dermatology,  
Reims, France<sup>(14)</sup> - Ch Argenteuil, Dermatology, Argenteuil, France<sup>(15)</sup> - Gem, Resopso,  
Paris, France<sup>(16)</sup>*

Use of biologic switching in clinical practice is needed to maximize skin clearance and improve clinical outcomes.

The aim of this study was to evaluate efficacy and safety of ixekizumab after discontinuation of secukinumab.

Inclusion criteria for this multicenter retrospective charts review included all adult patients with psoriasis treated by ixekizumab following discontinuation of secukinumab. The efficacy endpoint was achievement of PASI75 or PGA0/1 after 12 weeks of ixekizumab. Safety was evaluated by reported adverse events.

30 patients were included with mean age 51.3 years, sex ratio (H/F) was 0.76, mean BMI was 27.8. Psoriasis duration was 25.3 years, type of psoriasis was plaque (86.6%) and palmoplantar pustular (13.4%); 43.3% had psoriatic arthritis. Patients had failed 2.6 systemic and 2.9 biologic therapies before initiation of secukinumab. Mean secukinumab treatment duration was 9.4 months. Reasons for secukinumab discontinuation were primary failure(n=6), secondary failure(n=20), adverse event(n=3) and non-drug related reason(n=1).

Of the 30 secukinumab non responders, 70% responded to ixekizumab following 12 weeks of treatment. In subset analysis 83.3% primary non responders to secukinumab responded



to ixekizumab, compared to 65% secondary non responders and 50% of those who stopped secukinumab due other reason. 50% of patients with palmoplantar pustular psoriasis were non responders to ixekizumab compared to 23% of those with plaque psoriasis. In univariate analysis, only less important DLQI( $p=0.04$ ) and PGA( $p=0.03$ ) were associated with ixekizumab response at week 12.

9 patients reported one adverse event: injection site reaction( $n=4$ ), flare of pustular psoriasis( $n=2$ ), eczematiform eruption( $n=1$ ), Staphylococcus aureus cutaneous infection( $n=1$ ) and malaise( $n=1$ ). Of the 4 patients who experienced adverse event to both treatments, two subjects sustained an identical one: Staphylococcus aureus skin infection, eczematiform eruption.

Ixekizumab appears to be an effective option after failure of secukinumab, especially in patients with plaque psoriasis primary non responder to secukinumab.

